Anti-inflammatory role of DPP-4 inhibitors in a nondiabetic model of glomerular injury

American Journal of Physiology - Renal Physiology

Volumn 308, Issue 8, 2015, Pages F878-F887

  Higashijima, Yoshiki ^a   Tanaka, Tetsuhiro ^a   Yamaguchi, Junna ^a   Tanaka, Shinji ^a   Nangaku, Masaomi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Dipeptidyl peptidase 4; Glucagon like peptide 1; Nondiabetic kidney disease

Indexed keywords

ALOGLIPTIN; ANAGLIPTIN; CD68 ANTIGEN; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; INCRETIN; INSULIN; MONOCYTE CHEMOTACTIC PROTEIN 1; ANTIINFLAMMATORY AGENT; CD68 PROTEIN, RAT; DIFFERENTIATION ANTIGEN; DPP4 PROTEIN, MOUSE; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; LEUKOCYTE ANTIGEN; LYMPHOCYTE ANTIBODY; PEPTIDE; PIPERIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; URACIL; VENOM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; EX VIVO STUDY; GLOMERULONEPHRITIS; INFLAMMATORY CELL; INSULIN RELEASE; MALE; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEINURIA; RAT; RENAL PROTECTION; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; CELL LINE; CELL PROTECTION; CHEMOTAXIS; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; GLOMERULUS; IMMUNOLOGY; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTILYMPHOCYTE SERUM; CELL LINE; CHEMOKINE CCL2; CHEMOTAXIS; CYTOPROTECTION; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DISEASE MODELS, ANIMAL; GLOMERULONEPHRITIS; KIDNEY GLOMERULUS; MACROPHAGES, PERITONEAL; MALE; MICE, INBRED C57BL; PEPTIDES; PIPERIDINES; PROTEINURIA; PYRIMIDINES; RATS, SPRAGUE-DAWLEY; RECEPTORS, GLUCAGON; SIGNAL TRANSDUCTION; URACIL; VENOMS;

EID: 84927740133     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00590.2014     Document Type: Article

References (41)

1. Aizawa K, Tashiro Y, Hirata M, Takeda S, Kawasaki R, Endo K. Renoprotective effect of epoetin beta pegol by the prevention of M2 macrophage recruitment in Thy-1 rats. J Nephrol 27: 395–401, 2014.
2. Bunck MC, Corner A, Eliasson B, Heine RJ, Shaginian RM, Taskinen MR, Smith U, Yki-Jarvinen H, Diamant M. Effects of exenatide on measures of beta-cell function after 3 years in metformin-treated patients with type 2 diabetes. Diabetes Care 34: 2041–2047, 2011.
3. Cove-Smith A, Mulgrew CJ, Rudyk O, Dutt N, McLatchie LM, Shattock MJ, Hendry BM. Anti-proliferative actions of T-type calcium channel inhibition in Thy1 nephritis. Am J Pathol 183: 391–401, 2013.
4. Farilla L, Hui H, Bertolotto C, Kang E, Bulotta A, Di Mario U, Perfetti R. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 143: 4397–4408, 2002.
5. Fujita H, Morii T, Fujishima H, Sato T, Shimizu T, Hosoba M, Tsukiyama K, Narita T, Takahashi T, Drucker DJ, Seino Y, Yamada Y. The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential. Kidney Int 85: 579–589, 2014.
6. Glorie LL, Verhulst A, Matheeussen V, Baerts L, Magielse J, Hermans N, D’Haese PC, De Meester I, De Beuf A. DPP4 inhibition improves functional outcome after renal ischemia-reperfusion injury. Am J Physiol Renal Physiol 303: F681–F688, 2012.
7. Hegen M, Mittrucker HW, Hug R, Demuth HU, Neubert K, Barth A, Fleischer B. Enzymatic activity of CD26 (dipeptidylpeptidase IV) is not required for its signalling function in T cells. Immunobiology 189: 483–493, 1993.
8. Hendarto H, Inoguchi T, Maeda Y, Ikeda N, Zheng J, Takei R, Yokomizo H, Hirata E, Sonoda N, Takayanagi R. GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin- induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases. Metabolism 61: 1422–1434, 2012.
9. Hocher B, Sharkovska Y, Mark M, Klein T, Pfab T. The novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial ischemia/reperfusion in rats. Int J Cardiol 167: 87–93, 2013.
10. Hui H, Nourparvar A, Zhao X, Perfetti R. Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5=-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology 144: 1444–1455, 2003.
11. Ikezumi Y, Kanno K, Koike H, Tomita M, Uchiyama M, Shimizu F, Kawachi H. FK506 ameliorates proteinuria and glomerular lesions induced by anti-Thy 1.1 monoclonal antibody 1-22-3. Kidney Int 61: 1339–1350, 2002.
12. Ikezumi Y, Kawachi H, Toyabe S, Uchiyama M, Shimizu F. An anti-CD5 monoclonal antibody ameliorates proteinuria and glomerular lesions in rat mesangioproliferative glomerulonephritis. Kidney Int 58: 100–114, 2000.
13. Ikezumi Y, Suzuki T, Karasawa T, Hasegawa H, Kawachi H, Nikolic- Paterson DJ, Uchiyama M. Contrasting effects of steroids and mizoribine on macrophage activation and glomerular lesions in rat thy-1 mesangial proliferative glomerulonephritis. Am J Nephrol 31: 273–282, 2010.
14. Joo KW, Kim S, Ahn SY, Chin HJ, Chae DW, Lee J, Han JS, Na KY. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in rat remnant kidney. BMC Nephrol 14: 98, 2013.
15. Jungraithmayr W, De Meester I, Matheeussen V, Baerts L, Arni S, Weder W. CD26/DPP-4 inhibition recruits regenerative stem cells via stromal cell-derived factor-1 and beneficially influences ischaemia-reperfusion injury in mouse lung transplantation. Eur J Cardiothorac Surg 41: 1166–1173, 2012.
16. Katagiri D, Hamasaki Y, Doi K, Okamoto K, Negishi K, Nangaku M, Noiri E. Protection of glucagon-like peptide-1 in cisplatin-induced renal injury elucidates gut-kidney connection. J Am Soc Nephrol 24: 2034–2043, 2013.
17. Kodera R, Shikata K, Kataoka HU, Takatsuka T, Miyamoto S, Sasaki M, Kajitani N, Nishishita S, Sarai K, Hirota D, Sato C, Ogawa D, Makino H. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 54: 965–978, 2011.
18. Kodera R, Shikata K, Takatsuka T, Oda K, Miyamoto S, Kajitani N, Hirota D, Ono T, Usui HK, Makino H. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes. Biochem Biophys Res Commun 443: 828–833, 2014.
19. Lee B, Shi L, Kassel DB, Asakawa T, Takeuchi K, Christopher RJ. Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys. Eur J Pharmacol 589: 306–314, 2008.
20. Lee S, Huen S, Nishio H, Nishio S, Lee HK, Choi BS, Ruhrberg C, Cantley LG. Distinct macrophage phenotypes contribute to kidney injury and repair. J Am Soc Nephrol 22: 317–326, 2011.
21. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ. Glucagonlike peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 278: 471–478, 2003.
22. Liu WJ, Xie SH, Liu YN, Kim W, Jin HY, Park SK, Shao YM, Park TS. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin- induced diabetic rats. J Pharmacol Exp Ther 340: 248–255, 2012.
23. Lloyd CM, Minto AW, Dorf ME, Proudfoot A, Wells TN, Salant DJ, Gutierrez-Ramos JC. RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis. J Exp Med 185: 1371–1380, 1997.
24. Muskiet MH, Smits MM, Morsink LM, Diamant M. The gut-renal axis: do incretin-based agents confer renoprotection in diabetes? Nat Rev Nephrol 10: 88–103, 2014.
25. Ojima A, Ishibashi Y, Matsui T, Maeda S, Nishino Y, Takeuchi M, Fukami K, Yamagishi S. Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin- induced diabetic rats by blocking advanced glycation end productinduced protein arginine methyltranferase-1 expression. Am J Pathol 182: 132–141, 2013.
26. Oravecz T, Roderiquez G, Koffi J, Wang J, Ditto M, Bou-Habib DC, Lusso P, Norcross MA. CD26 expression correlates with entry, replication and cytopathicity of monocytotropic HIV-1 strains in a T-cell line. Nat Med 1: 919–926, 1995.
27. Park CW, Kim HW, Ko SH, Lim JH, Ryu GR, Chung HW, Han SW, Shin SJ, Bang BK, Breyer MD, Chang YS. Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice. J Am Soc Nephrol 18: 1227–1238, 2007.
28. Rampino T, Soccio G, Gregorini M, Guidetti C, Marasa M, Maggio M, Panichi V, Migliori M, Libetta C, Dal Canton A. Neutralization of macrophage-stimulating protein ameliorates renal injury in anti-thy 1 glomerulonephritis. J Am Soc Nephrol 18: 1486–1496, 2007.
29. Sean Eardley K, Cockwell P. Macrophages and progressive tubulointerstitial disease. Kidney Int 68: 437–455, 2005.
30. Shinosaki T, Kobayashi T, Kimura K, Kurihara H. Involvement of dipeptidyl peptidase IV in immune complex-mediated glomerulonephritis. Lab Invest 82: 505–513, 2002.
31. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 122: 787–795, 2012.
32. Sivertsen J, Rosenmeier J, Holst JJ, Vilsboll T. The effect of glucagonlike peptide 1 on cardiovascular risk. Nat Rev Cardiol 9: 209–222, 2012.
33. Swenson-Fields KI, Vivian CJ, Salah SM, Peda JD, Davis BM, van Rooijen N, Wallace DP, Fields TA. Macrophages promote polycystic kidney disease progression. Kidney Int 83: 855–864, 2013.
34. Tajima T, Murata T, Aritake K, Urade Y, Hirai H, Nakamura M, Ozaki H, Hori M. Lipopolysaccharide induces macrophage migration via prostaglandin D2 and prostaglandin E2. J Pharmacol Exp Ther 326: 493–501, 2008.
35. Takase O, Hishikawa K, Kamiura N, Nakakuki M, Kawano H, Mizuguchi K, Fujita T. Eicosapentaenoic acid regulates IB and prevents tubulointerstitial injury in kidney. Eur J Pharmacol 669: 128–135, 2011.
36. Tanaka T, Higashijima Y, Wada T, Nangaku M. The potential for renoprotection with incretin-based drugs. Kidney Int 86: 701–711, 2014.
37. Tesch GH, Maifert S, Schwarting A, Rollins BJ, Kelley VR. Monocyte chemoattractant protein 1-dependent leukocytic infiltrates are responsible for autoimmune disease in MRL-Fas(lpr) mice. J Exp Med 190: 1813–1824, 1999.
38. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and +-cell function in type 2 diabetes: a parallel-group study. Lancet 359: 824–830, 2002.
39. Zaruba MM, Theiss HD, Vallaster M, Mehl U, Brunner S, David R, Fischer R, Krieg L, Hirsch E, Huber B, Nathan P, Israel L, Imhof A, Herbach N, Assmann G, Wanke R, Mueller-Hoecker J, Steinbeck G, Franz WM. Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction. Cell Stem Cell 4: 313–323, 2009.
40. Zhang MZ, Yao B, Yang S, Jiang L, Wang S, Fan X, Yin H, Wong K, Miyazawa T, Chen J, Chang I, Singh A, Harris RC. CSF-1 signaling mediates recovery from acute kidney injury. J Clin Invest 122: 4519–4532, 2012.
41. Zhang Z, Wang Z, Ren H, Yue M, Huang K, Gu H, Liu M, Du B, Qian M. P2Y6 agonist uridine 5=-diphosphate promotes host defense against bacterial infection via monocyte chemoattractant protein-1-mediated monocytes/macrophages recruitment. J Immunol 186: 5376–5387, 2011.